



Drug Formulary Update
April 2024

Updates to the HealthPartners Commercial Drug Formularies are listed below.

Please see www.healthpartners.com/formularies for details.

Updates are effective by April 1, 2024.

This table shows formulary status, with prior authorization and quantity limits.

Drug name	Current Status	New Status	Comments
Adalimumab-aaty (Yuflyma) Adalimumab-adaz (Hyrimoz) Adalimumab-adbm (Cyltezo)		NF-PA-QL	Non-preferred Humira biosimilars.
Albuterol/ budesonide (Airsupra)		NF-PA	
Alirocumab (Praluent)	NF PA	NF PA QL	PA update, and adding a quantity limit.
Amphetamine (Adzenys)	NF PA QL	NF PA QL	PA update.
Belumosudil (Rezurock)	F PA QL	F PA QL	Removed from oncology policy.
Bexagliflozin (Brenzavvy)		NF-PA-QL	
Brimonidine (Alphagan P 0.1%)	F	NF PA	The equivalent generic is preferred.
Colchicine 0.5mg (Lodoco)		NF-PA	
Daprodustat (Jesduvroq)		NF-PA	
Emollient combination no. 10 (Luxamend)	NF PA	EXCL	
Fluoride (Clinpro 5000, Fluoridex)	NF	EXCL	
Fluticasone/ vilanterol (Breo Ellipta), 50-25 mcg		F	Breo is included in the Enhanced HSA program.
Hydrocortisone (Alkindi)	NF PA	EXCL/ NF PA, SP	Hydrocortisone tablets are preferred.
Hydromorphone	NF QL	NF QL	Decrease quantity limit, in alignment with CDC guidelines.
Insulin degludec	NF PA	NF PA	PA update.
Lacosamide (Motpoly XR)		NF-PA	
Latanoprost PF (Iyuzeh)		NF-PA	
Lisdexamfetamine (Vyvanse)	F QL	NF PA QL	The equivalent generic is preferred.
Lopinavir/ ritonavir (Kaletra)	F	NF	The equivalent generic is preferred.
Lotilaner (Xdemvy)		NF-PA	
Miglustat (Opfolda)		NF-PA-QL	
Milnacipran (Savella)	F PA QL	F PA QL	PA update.

Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step-Therapy, QL = Quantity Limit, AGE = Age Limit. EXCL = Excluded.

The current formulary status is empty for new FDA-approvals.

HSA: Health Spending Account Preventive Drug Program.

ACA: covered under the Affordable Care Act.

Drug name	Current Status	New Status	Comments
Momelotinib (Ojjaara)		NF-PA	
Nalmefene (Opvee)		F	
Naloxone OTC	OTC	F	
Niraparib/ abiraterone (Akeega)		F-PA	
Nirsevimab (Beyfortus)		F	Beyfortus is included in the ACA preventive program.
Nitazoxanide (Alinia) suspension	F PA	NF PA QL	Tablets are preferred.
Nitazoxanide tablet	F PA	F PA QL	Adding a quantity limit.
Peg 3350/ sod sulf/ pot/ mag (Suflave)		NF	
Potassium chloride (Pokonza)		NF-PA	
Quizartinib (Vanflyta)		F-PA	
Ritlecitinib (Litfulo)		NF-PA-QL	
Rotigotine (Neupro)	F PA	F PA	PA update.
RSV vaccine (Abrysvo)		F	Abrysvo is included in the ACA preventive program.
RSV vaccine (Arexvy)		F	Arexvy is included in the ACA preventive program.
Saxagliptin		NF-PA-QL	
Saxagliptin/ metformin		NF-PA-QL	
Selumetinib (Koselugo)	F PA QL	F PA QL	Removed from oncology policy.
Sodium oxybate (Lumryz, Xywav, Xyrem, and generic)	NF PA QL	NF PA QL	PA update.
Somatrogon (Ngenla)		NF-PA	
Somatropin (Genotropin)	NF PA	F PA	Genotropin has been added to the formulary.
Tiotropium		NF-PA	

Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step-Therapy, QL = Quantity Limit, AGE = Age Limit. EXCL = Excluded.

The current formulary status is empty for new FDA-approvals.

HSA: Health Spending Account Preventive Drug Program.

ACA: covered under the Affordable Care Act.